The Death of the Genus Claim

D Karshtedt, MA Lemley, SB Seymore - Harv. JL & Tech., 2021 - HeinOnline
The central feature of patent law in the chemical, biotechnology, and pharmaceutical
industries is the genus claim-a patent claim that covers not just one specific chemical but a …

The cost of novelty

W Price, II Nicholson - Colum. L. Rev., 2020 - HeinOnline
Patent law promotes innovations that are different from what the world already knows. This
may seem a truism: What is innovation other than the search for new things? 1 But mere …

Costly gadgets: barriers to market entry and price competition for generic drug-device combinations in the United States

MS Sinha - Minn. JL Sci. & Tech., 2021 - HeinOnline
Prescription drug prices continue to rise unabated in the United States, largely due to a
system that allows brand-name drug makers to charge whatever the market will bear. Some …

Whom do prosecutors protect?

VB Johnson - BUL Rev., 2024 - HeinOnline
Prosecutors regard themselves as public servants who fight crime and increase community
safety on behalf of their constituents. But prosecutors do not only seek to protect those they …

Nonobviousness: Before and After

D Karshtedt - Iowa L. Rev., 2020 - HeinOnline
The requirement of nonobviousness, codified in 35 USC § 103, has been called" the
ultimate condition of patentability" because of its crucial function of keeping technically trivial …

Taking Artificial Intelligence Beyond the Turing Test

PM Reinbold - Wis. L. Rev., 2020 - HeinOnline
In thinking about artificial intelligence, many people imagine (and fear) fully autonomous
and sentient artificial general intelligence. In thinking about the patentability of inventions by …

Off-label preemption

DA Simon - Wis. L. Rev., 2024 - HeinOnline
In 2002, the Food and Drug Administration (FDA) approved a new medical device, InFuse
Bone Graft, for use in operations to fuse the lumbar spine of adults with deteriorating …

Prior Art in the District Court

S Yelderman - Notre Dame L. Rev., 2019 - HeinOnline
The conclusions here are mixed. On one hand, invalidations for lack of novelty bear many
indicia of publicly beneficial error correction. Anticipation based on obscure prior art appears …

Off-Label Innovation

DA Simon - Ga. L. Rev., 2021 - HeinOnline
In 1966, the Food and Drug Administration (FDA) approved the drug amantadine
hydrochloride (amantadine) for the prevention of Asian influenza A (H2N2). J Doctors began …

Prior art in inter partes review

S Yelderman - Iowa L. Rev., 2018 - HeinOnline
This Essay is an empirical study of the evidence the Patent Trial and Appeal Board relies
upon when cancelling patents in inter partes review. To construct our dataset, we collected …